Nile Therapeutics, Inc
4 West 4th Avenue
Suite 400
San Mateo,
CA 94402
United States - Map
Phone: 650-458-2670
Fax: 415-875-7075
Web Site: http://www.nilethera.com
| Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide. The company was founded in 2005 and is based in San Mateo, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Peter Morgan Kash , 47
Co-Founder, Chairman, Chairman of Nominating & Corp. Governance Committee and Member of Compensation Committee |
$
0 | N/A | Mr. Joshua A. Kazam ,
Co-Founder, Chief Exec. Officer, Pres |
$
0 | N/A | Mr. David M. Tanen , 37
Co-Founder and Sec. |
$
0 | N/A | Mr. Daron Evans , 36
Chief Financial Officer and Principal Accounting Officer |
$
175.00K | N/A | Dr. Hsiao Dee Lieu M.D., F.A.C.C., 39
VP of Clinical Research |
$
258.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
0.04 (2.88%) 
Profile
